/CNW Telbec/ - Today, Bristol Myers Squibb Canada (BMS) announced Health Canada s approval of OPDIVO® (nivolumab) 360 mg every three weeks or 3mg/kg every two.
NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb Canada Co., an indirect wholly-owned subsidiary of Bristol Myers Squibb Co. (BMY) announced Wednesday Health Canada's approval of OPDIVO (nivolumab)
First new systemic therapy in more than 15 years for cancer related to asbestos exposure Today, Bristol Myers Squibb Canada announced Health Canada's approval of OPDIVO ® 360 mg every three weeks or 3mgkg every two weeks plus YERVOY ® 1 mgkg every six weeks for the treatment of adult patients with unresectable malignant pleural mesothelioma who have not received prior systemic therapy for MPM. i This is the .
Form 6-K Profound Medical Corp For: May 19 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.